ArticleAnnals of hematology2026
Synergistic adverse prognostic impact of CD30 and Epstein-Barr virus in peripheral T-cell lymphoma: CD30 identifies a high-risk subgroup in Epstein-Barr virus-encoded RNA -positive patients.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with Epstein–Barr virus–encoded RNA (EBER)-positive Peripheral T-cell lymphoma (PTCL) exhibit poor survival. Current prognostic scores lack efficacy in this group, necessitating more specific biological markers. This multicenter retrospective cohort study evaluated the prognostic significance of CD30 status in EBER-positive angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) patients. Receiver operating characteristic (ROC) analysis, Kaplan–Meier survival curves, and Cox regression analysis were employed to assess the predictive value of CD30 expression relative to conventional clinical indices. A total of 120 PTCL patients were included, among whom 47 were EBER-positive. The EBER/CD30 distribution was as follows: CD30⁻EBER⁺ 14.2% (17/120); CD30⁺EBER⁺ 25.0% (30/120); CD30⁻EBER⁻ 30.0% (36/120) and CD30⁺EBER⁻ 30.8% (37/120). The CD30⁺EBER⁺ subgroup demonstrated significantly inferior survival and treatment response, with a 3-year overall survival (OS) rate of only 6.9% (95% CI: 1.2%–37.9%), markedly lower than other subgroups (p < 0.0001). Chidamide combined with CHOP-like chemotherapy suggest a potential survival benefit in this subgroup compared to CHOP-like chemotherapy (median OS: 19.1 vs.7.3 months). Among EBER-positive PTCL patients, multivariable analysis confirmed CD30 positivity as an independent prognostic factor (p = 0.023). The 3-year AUC for CD30 was 0.742, with a sensitivity of 0.726 and specificity of 0.758, outperforming conventional clinical indicators. This multicenter cohort study identifies the CD30⁺EBER⁺ subgroup as a highly aggressive PTCL phenotype with particularly poor prognosis. CD30 positivity remains an independent risk factor, enabling the identification of a high-risk EBER-positive patient subset and providing a rationale for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.